Acute Upper Respiratory Infection
10
0
0
6
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
0.0%
0 terminated out of 10 trials
100.0%
+13.5% vs benchmark
40%
4 trials in Phase 3/4
0%
0 of 6 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 6 completed trials
Clinical Trials (10)
Evaluating the Potential of Large Language Models for Respiratory Disease Consultations
Treatment of Influenza and ARVI in Children by Kagocel ®
Clinical Trial to Assess the Efficacy and Safety of MUCOLASE Tablet(Streptokinase • Streptodornase)
Phase IV Trial,The Efficacy and Safety Study of Fuganlin Oral Liquid in Children With Acute Upper Respiratory Infection
The Efficacy and Safety Study of Fuganlin Oral Liquid in Children With Influenza (Acute Upper Respiratory Infection)
Impact of Introduction of PHiD-CV for Nunavik Children, Quebec, Canada
Treatment of Influenza in Routine Clinical Practice
Phase 3 Study of Pelubiprofen & Loxoprofen in Patients With Upper Respiratory Tract Infection
A Post-marketing Research on Jinyebaidu Granule in Treating Patients With Acute Upper Respiratory Infection
Comparison of Supportive Therapies for Symptom Relief From Pediatric Upper Respiratory Infections (URIs)